Athena Diagnostics Overview
- Founded
-
1989
- Status
-
Acquired/Merged
- Employees
-
300
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
Athena Diagnostics General Information
Description
Developer and provider of proprietary molecular diagnostic and immunodiagnostic tests and services. The company provides advanced neurological diagnostic assays. It provides diagnosis on peripheral nerve disorders, neurogenetic disorders, Alzheimer's disease, paraneoplastic syndromes, movement disorders, neuromuscular disorders, and ataxia.
Contact Information
Website
www.athenadiagnostics.com
Formerly Known As
Genica Pharmaceuticals
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Other Healthcare Services
Parent Company
Primary Office
- Four Biotech Park
- 377 Plantation Street
- Worcester, MA 01605
- United States
+1 (508) 000-0000
Athena Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Athena Diagnostics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer and provider of proprietary molecular diagnostic and immunodiagnostic tests and services. The company provides
Laboratory Services (Healthcare)
Worcester, MA
300
As of 2011
0000
0000-00-00
000000&0
000000
o laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
000000000000000000 00000000
Frankfurt, Germany
00
As of 0000
0000
0000-00-00
000000000000
Add Comparison
Athena Diagnostics Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 0000000 0000000000 | Private Equity-Backed | Frankfurt, Germany | 00 | 000000000000 |
Athena Diagnostics Patents
Athena Diagnostics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6537505-B2 | Virulence scoring system for human clinical genetics | Active | 22-Oct-2013 | 000000000 | |
| JP-2017504846-A | Pathogenicity scoring system for human clinical genetics | Granted | 22-Oct-2013 | 000000000 | |
| US-20200411134-A1 | Pathogenicity scoring system for human clinical genetics | Pending | 22-Oct-2013 | 000000000 | |
| US-10762981-B2 | Pathogenicity scoring system for human clinical genetics | Active | 22-Oct-2013 | 000000000 | 0 |
| EP-3061020-A1 | Pathogenicity scoring system for human clinical genetics | Pending | 22-Oct-2013 | G16B20/00 |
Athena Diagnostics Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jeffrey Weisberg | Chief Financial Officer & Senior Vice President, Financial Operations |
Athena Diagnostics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Athena Diagnostics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|